MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

A recent study by Limagne et al.(1) in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.